Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 2Urinary Bladder Neoplasms 1Recurrence 1Rare Tumour 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Muscle Invasive Bladder Urothelial Carcinoma 1Multiple Myeloma 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Gemcitabine 15Mitomycin 10Docetaxel 7BCG Vaccine 7Cystoscopy 4tislelizumab 3durvalumab 3Radiotherapy 3Epirubicin 3disitamab vedotin 2avelumab 2Hyaluronic Acid 2tremelimumab 1toripalimab 1pemigatinib 1pembrolizumab 1monalizumab 1lornoxicam 1erdafitinib 1enzalutamide 1chondroitin sulfate, sodium hyaluronate drug combination 1bicalutamide 1Watchful Waiting 1VPM1002 recombinant BCG vaccine 1Urine Specimen Collection 1Ty21a typhoid vaccine 1Transurethral Resection of Bladder 1Therapeutics 1Surveys and Questionnaires 1Sugars 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Non-Muscle Invasive Bladder Neoplasms × erdafitinib × Clear all
NCT04917809 2026-04-22

A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
20 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡